Myriad Genetics, Inc. is a molecular diagnostic company, which focuses on developing and marketing of novel predictive and personalized medicines and prognostic medicine tests. It operates through ...

Myriad Genetics (MYGN) and Lumea have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests – Prolaris Prostate Cancer ...

Researchers at the University of Toronto have invented a new method that uses DNA sequencing to measure metabolites. This ...

The study objective is to provide current estimates of utilization/spending trends for molecular diagnostic and genetic testing for commercially insured, Medicare and Medicaid populations.

(RTTNews) - Mainz Biomed N.V. (MYNZ), a molecular genetics diagnostic company, announced on Monday, that it has regained compliance with Nasdaq's continued listing requirements. The company ...

This collaboration will streamline the ordering and delivery of molecular tests, enabling healthcare providers to ...

15 am-12:15 pm Gerstenzang 124 Molecular Genetics Journal Club (Engineering Faculty Search) Duane Juang, PhD (Quantum Diamond Technologies Inc) "Developing enabling technologies for infectious disease ...

BERKELEY, Calif. and MAINZ, Germany, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing ...

Public awareness and advancements in diagnostics have improved our understanding ... CR amplifies small amounts of viral genetic material in a patient sample, making detecting even low virus ...

Antibiotic resistance is a global public health crisis responsible for more than a million deaths annually. By 2050, the World Health Organization estimates it could surpass cancer and heart disease ...